Clinical comprehensive evaluation of four Chinese patent medicines in the treatment of hyperlipidemia
- VernacularTitle:4种治疗高脂血症中成药的临床综合评价
- Author:
Mingzhu ZHANG
1
;
Yizhuo QIN
2
;
Xianshuai TANG
2
;
Lei ZHENG
2
;
Jinfang SONG
3
Author Information
1. Dept. of Pharmacy，Shandong Provincial Third Hospital Affiliated to Shandong University，Jinan 250031，China;Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy，Xuzhou Medical University，Jiangsu Xuzhou 221004，China
2. Dept. of Pharmacy，Shandong Provincial Third Hospital Affiliated to Shandong University，Jinan 250031，China
3. Dept. of Pharmacy，the Affiliated Hospital of Jiangnan University，Jiangsu Wuxi 214122，China
- Publication Type:Journal Article
- Keywords:
hyperlipidemia;
Chinese patent medicine;
clinical comprehensive evaluation;
Xuezhikang;
Zhibitai;
Zhibituo
- From:
China Pharmacy
2026;37(6):708-712
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the clinical comprehensive value of four Chinese patent medicines （Xuezhikang， Zhibitai， Zhibituo， Jiangzhiling） in the treatment of hyperlipidemia， and provide a reference for rational clinical drug use. METHODS A clinical comprehensive evaluation index system was established in accordance with the Evidence and Value： Impact on Decision-Making （EVIDEM） framework and Technical Guideline for Clinical Comprehensive Evaluation of Cardiovascular Drugs （2022 edition， trial implementation）. CNKI， Wanfang data， VIP， PubMed， ScienceDirect， Embase and official websites were retrieved to collect the literature such as drug instructions， guidelines and consensus statements， and systematic reviews/meta-analyses for the four Chinese patent medicines. A comprehensive evaluation was conducted from seven dimensions： effectiveness， safety， economy， suitability， accessibility， innovation and characteristics of traditional Chinese medicine. RESULTS This evaluation index system included 7 first-level indicators， 15 second-level indicators and 30 third-level indicators. Xuezhikang achieved the highest comprehensive evaluation score of 81.4 points， and was classified as class Ⅰ recommendation. Zhibitai with 76.0 points and Zhibituo with 60.9 points were both classified as class Ⅱ recommendation. Jiangzhiling with 48.8 points was classified as class Ⅳ recommendation. CONCLUSIONS Xuezhikang demonstrates the optimal clinical comprehensive value for treating hyperlipidemia. Zhibitai exhibits certain advantages in terms of safety and characteristics of traditional Chinese medicine； Zhibituo shows a moderate performance in all aspects； Jiangzhiling has a relatively low score. Appropriate medicines can be selected clinically according to actual conditions and patients’ characteristics.
